Phototherapy News and Research

RSS

Universal bilirubin screening can reduce jaundice incidence in newborns

Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.

28 Sep 2009

Nomir publishes efficacy of the Noveondual-wavelength device against infectious disease pathogens

Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data.

16 Sep 2009

New treatment for facial wrinkles combines high-intensity light and green tea extract lotion

Scientists in Germany are reporting a major improvement in their potential new treatment for facial wrinkles that could emerge as an alternative to Botox and cosmetic surgery. The non-invasive technique combines high-intensity light from light-emitting diodes (LEDs) and a lotion made of green tea extract. It works ten times faster than a similar anti-wrinkle treatment that uses LEDs alone, the researchers say.

10 Sep 2009

Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis

For patients with psoriasis, treatment with ultraviolet B (UVB) at home is as effective and as safe as conventional hospital based phototherapy, concludes a study published on bmj.com today.

7 May 2009

Researchers at the UJI increase the efficiency of photocatalysts used in cancer treatments

Researchers at the Universitat Jaume I (UJI) in Castellon have found porous polymeric materials that increase the efficiency of traditional photocatalysts in the treatment of cancer.

6 Apr 2009

Jaundice an unreliable method of predicting the baby's risk of hyperbilirubinemia

For hundreds of years, doctors, nurses and midwives have visually examined newborn babies for the yellowish skin tones that signify jaundice, judging that more extensive jaundice carried a greater risk of illness.

23 Mar 2009

FDA issues warning on psoriasis drug Raptiva (efalizumab)

The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).

20 Feb 2009

FDA issues complete response to biologics license application for ustekinumab

Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab.

21 Dec 2008

Earlier jaundice treatment decreases brain injury in preterm infants

A study from a National Institutes of Health research network found that an early treatment to prevent severe newborn jaundice in extremely early preterm infants reduced the infants' rate of brain injury, a serious complication of severe jaundice.

30 Oct 2008

FDA approves new labeling for psoriasis drug Raptiva

The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.

19 Oct 2008

UV light therapy is as beneficial for darker skin as lighter skin

An analysis of more than 100 patients has confirmed for the first time that darker-skinned patients benefit as those with lighter skin when given light therapy for morphea and related diseases, UT Southwestern Medical Center researchers show.

8 Jul 2008

Light-powered nanomachine kills cancer cells

Researchers from the Nano Machine Center at the California NanoSystems Institute at UCLA have developed a novel type of nanomachine that can capture and store anticancer drugs inside tiny pores and release them into cancer cells in response to light.

2 Apr 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

Enbrel shown to significantly reduced levels of C-reactive protein

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group.

5 Feb 2008

Simple test accurately predicts risk of serious jaundice in newborns

A simple test can accurately identify which newborn babies are at risk for developing dangerous levels of jaundice, according to researchers at The Children's Hospital of Philadelphia.

11 Jan 2008

Light-activated molecules used to induce apoptosis in cancer cells

A key challenge facing doctors as they treat patients suffering from cancer or other diseases resulting from genetic mutations is that the drugs at their disposal often don't discriminate between healthy cells and dangerous ones -- think of the brute-force approach of chemotherapy, for instance.

12 Aug 2007

Efalizumab effective in treatment of heavy psoriasis

A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis, had an acceptable safety and efficacy profile in the treatment of psoriasis in heavy patients, researchers at Mount Sinai School of Medicine announced today.

3 Aug 2007